Evidence that tirzepatide protects against diabetes-related cardiac damages.

What the trial testedas reported · 2024

Not counted

−41%−60% to −21%

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.59, 95% CI 0.40–0.79

the abstract, start to end

… for MACE events by TZT therapy (HR was 0.59 (95% CI 0.40-0.79, …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

HR 0.590.40–0.79

GIP/GLP-1 & amylin agonistsCardiovascular events

1 / 3

2024

2025

2026

this paperpooled itcites it